• Je něco špatně v tomto záznamu ?

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

M. Boegemann, S. Khaksar, G. Bera, A. Birtle, C. Dopchie, LM. Dourthe, E. Everaert, M. Hatzinger, D. Hercher, W. Hilgers, G. Matus, LG. Alvarez, L. Antoni, M. Lukac, G. Pissart, P. Robinson, T. Elliott,

. 2019 ; 19 (1) : 60. [pub] 20190114

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19027910

Grantová podpora
n/a Janssen Pharmaceutica NV

BACKGROUND: With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice. This study primarily aimed to describe the time to treatment failure (TTF) of mCRPC patients treated with abiraterone acetate plus prednisone or the corticosteroid of choice (AAP) in the pre-chemotherapy setting. Other relevant outcomes, clinical and treatment characteristics of these patients were also evaluated. METHODS: This retrospective, observational study collected data from chemotherapy-naïve mCRPC patients treated with AAP from four European countries. Kaplan-Meier curves were used to estimate TTF, progression-free survival (PFS), and time to first skeletal-related event. The impact of baseline characteristics on TTF and PFS was explored using univariate and multivariate Cox proportional hazard models. Log-rank test was used to assess the potential role of duration of response to ADT in predicting response to AAP treatment. RESULTS: Data from 481 eligible patients (Belgium: 68; France: 61; Germany: 150; UK: 202) were analysed. At AAP initiation, the median age of patients was 75.0 years (interquartile range [IQR]: 69.0-81.0), and the median PSA was 56.2 ng/mL (IQR: 22.2-133.1), with over 50% of patients presenting an ECOG score of 0 or 1. Visceral metastases were present in 7.5% of patients; an exclusion criterion in the COU-AA-302 clinical trial. The median TTF with AAP was 10.0 months (95%CI: 9.2-11.1) and the median PFS was 10.8 months (95%CI: 9.6-11.8). Shorter TTF was significantly associated with higher ALP (> 119 units/L), higher PSA (> 56.2 ng/mL), or poorer ECOG PS scores at AAP initiation (p < 0.05). Patients with longer duration of response to ADT (≥12 months) presented longer TTF and longer time to progression (p < 0.0001). CONCLUSIONS: This European real-world study provides valuable insights into the characteristics, treatment, and outcomes of chemotherapy-naïve patients with mCRPC who received AAP in routine clinical practice. Treatment effectiveness of AAP in the real-world is maintained despite patients having poorer clinical features at initiation than those observed in the COU-AA-302 trial population.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19027910
003      
CZ-PrNML
005      
20190820095109.0
007      
ta
008      
190813s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-019-5280-6 $2 doi
035    __
$a (PubMed)30642291
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Boegemann, Martin $u Department of Urology, University of Muenster Medical Center, Albert-Schweitzer-Campus 1, GB A1, D-48149, Muenster, Germany. Martin.Boegemann@ukmuenster.de.
245    10
$a Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study / $c M. Boegemann, S. Khaksar, G. Bera, A. Birtle, C. Dopchie, LM. Dourthe, E. Everaert, M. Hatzinger, D. Hercher, W. Hilgers, G. Matus, LG. Alvarez, L. Antoni, M. Lukac, G. Pissart, P. Robinson, T. Elliott,
520    9_
$a BACKGROUND: With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice. This study primarily aimed to describe the time to treatment failure (TTF) of mCRPC patients treated with abiraterone acetate plus prednisone or the corticosteroid of choice (AAP) in the pre-chemotherapy setting. Other relevant outcomes, clinical and treatment characteristics of these patients were also evaluated. METHODS: This retrospective, observational study collected data from chemotherapy-naïve mCRPC patients treated with AAP from four European countries. Kaplan-Meier curves were used to estimate TTF, progression-free survival (PFS), and time to first skeletal-related event. The impact of baseline characteristics on TTF and PFS was explored using univariate and multivariate Cox proportional hazard models. Log-rank test was used to assess the potential role of duration of response to ADT in predicting response to AAP treatment. RESULTS: Data from 481 eligible patients (Belgium: 68; France: 61; Germany: 150; UK: 202) were analysed. At AAP initiation, the median age of patients was 75.0 years (interquartile range [IQR]: 69.0-81.0), and the median PSA was 56.2 ng/mL (IQR: 22.2-133.1), with over 50% of patients presenting an ECOG score of 0 or 1. Visceral metastases were present in 7.5% of patients; an exclusion criterion in the COU-AA-302 clinical trial. The median TTF with AAP was 10.0 months (95%CI: 9.2-11.1) and the median PFS was 10.8 months (95%CI: 9.6-11.8). Shorter TTF was significantly associated with higher ALP (> 119 units/L), higher PSA (> 56.2 ng/mL), or poorer ECOG PS scores at AAP initiation (p < 0.05). Patients with longer duration of response to ADT (≥12 months) presented longer TTF and longer time to progression (p < 0.0001). CONCLUSIONS: This European real-world study provides valuable insights into the characteristics, treatment, and outcomes of chemotherapy-naïve patients with mCRPC who received AAP in routine clinical practice. Treatment effectiveness of AAP in the real-world is maintained despite patients having poorer clinical features at initiation than those observed in the COU-AA-302 trial population.
650    _2
$a abirateron $x aplikace a dávkování $7 D000069501
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a komorbidita $7 D015897
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a staging nádorů $7 D009367
650    _2
$a prednison $x aplikace a dávkování $7 D011241
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a nádory prostaty rezistentní na kastraci $x farmakoterapie $x mortalita $x patologie $7 D064129
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Khaksar, Sara $u St Luke's Cancer Centre, The Royal Surrey County Hospital, Guildford, UK.
700    1_
$a Bera, Guillaume $u Groupe Hospitalier Bretagne Sud, Hôpital du Scorff, Lorient, France.
700    1_
$a Birtle, Alison $u Rosemere Cancer Centre, Royal Preston Hospital & University of Manchester, Manchester, UK.
700    1_
$a Dopchie, Catherine $u CHWapi site IMC, Tournai, Belgium.
700    1_
$a Dourthe, Louis-Marie $u Clinique Saint Anne, Strasbourg, France.
700    1_
$a Everaert, Els $u AZ Nikolaas, Sint Niklaas, Belgium.
700    1_
$a Hatzinger, Martin $u Agaplesion Markus Hospital, Frankfurt, Germany.
700    1_
$a Hercher, Dirko $u Refrath Urological Center, Bergisch Gladbach, Germany.
700    1_
$a Hilgers, Werner $u Institut Sainte Catherine, Avignon, France.
700    1_
$a Matus, Geoffrey $u CHC Cliniques Saint Joseph, Liège, Belgium.
700    1_
$a Alvarez, Laura Garcia $u IQVIA, Barcelona, Spain.
700    1_
$a Antoni, Laurent $u Janssen Pharmaceutica NV, Beerse, Belgium.
700    1_
$a Lukac, Martin $u PAREXEL International, Prague, Czech Republic.
700    1_
$a Pissart, Geneviève $u Janssen Pharmaceutica NV, Beerse, Belgium.
700    1_
$a Robinson, Paul $u Janssen EMEA, London, High Wycombe, UK.
700    1_
$a Elliott, Tony $u The Christie Hospital, Manchester, UK.
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 19, č. 1 (2019), s. 60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30642291 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190820095344 $b ABA008
999    __
$a ok $b bmc $g 1433059 $s 1066370
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 19 $c 1 $d 60 $e 20190114 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
GRA    __
$a n/a $p Janssen Pharmaceutica NV
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace